Nivolumab in Combination With Ipilimumab in Patients With Metastatic Renal Cell Carcinoma

Summary

Immunotherapy with checkpoint inhibitors that target PD-1 and CTLA-4 have shown activity in mRCC. However, the optimal schedule of the combination therapy has yet to be defined. The objective of the trial is to determine the efficacy of combination immunotherapy of nivolumab and ipilimumab in patients with metastatic renal cell carcinoma. The expansion phase shall address the role of ipilimumab in case of clinically insignificant progression.

Timeline

Start

2017-12-13

Primary completion

2019-07-01

Completion

2025-04-30

Drugs

Indications